Incidence and Predictors of Thrombotic Events in Secondary Myelofibrosis
Researchers sought to characterize the incidence and risk factors for thrombotic events in patients with secondary myelofibrosis.
Myelofibrosis
Study Advances Knowledge Base About Children and Adolescents With Myeloproliferative Neoplasms
The researchers uncovered higher-than-anticipated rates of thrombosis, hemorrhage, and transformation in their real-world cohort of MPN patients.
Parsaclisib Improved Myelofibrosis Symptoms in Patients With Suboptimal Response to Ruxolitinib
At 12 weeks, most patients had a reduction in spleen volume.
LCL161 Shows Moderately Positive Objective Response Rate in Patients With Myelofibrosis
Researchers sought to determine whether LCL161 would induce a response in patients with myelofibrosis.
Depression Common Among Patients With a Myeloproliferative Neoplasm
Using validated tools, investigators determined that patients with a MPN were likely to experience significant symptoms of depression.
Cutaneous AEs Are Common in Patients With MPNs Treated With Hydroxyurea
Previously conducted retrospective studies may have underestimated the incidence of hydroxyurea-related skin toxicity in patients with MPNs.
Characteristics of Ruxolitinib Discontinuation Syndrome in Myelofibrosis
Ruxolitinib discontinuation syndrome was associated with spleen length and platelet count, although severe cases were rare in a cohort of patients with myelofibrosis.
Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Management of Patients With Myelofibrosis Experiencing Ruxolitinib Failure
Identification of the underlying pattern for ruxolitinib failure in patients with myelofibrosis is a significant factor in determining appropriate treatment.
Second Cancers Pose Significant Mortality Risk in Myeloproliferative Neoplasms
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...